SALES AGREEMENTSales Agreement • September 29th, 2023 • Inventiva S.A. • Pharmaceutical preparations • New York
The undersigned, the duly qualified and elected Chief Executive Officer of Inventiva S.A., a société anonyme incorporated in France (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section 4(p) of the Sales Agreement, dated September 28, 2023, between the Company and Cowen and Company, LLC (the “Sales Agreement”), that to the knowledge of the undersigned:
INVENTIVA (EGFF) Finance Contract between the European Investment Bank and Inventiva S.A.Inventiva S.A. • May 16th, 2022 • Pharmaceutical preparations
The European Investment Bank having its seat at 100 blvd Konrad Adenauer, Luxembourg, L-2950 Luxembourg, represented by Maria Teresa Massaad (Head of Division) and Antoine de Lachaux (Investment Officer) (the "Bank")
ORDINARY SHARES, PAR VALUE €0.01 PER SHARE [·] AMERICAN DEPOSITARY SHARESUnderwriting Agreement • July 6th, 2020 • Inventiva S.A. • Pharmaceutical preparations • New York
The ADSs purchased by the Underwriters hereunder shall be issued pursuant to a deposit agreement to be dated as of the Closing Date (as defined in Section 2) (the “Deposit Agreement”) by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”) and all holders and beneficial owners of the ADSs issued thereunder. Each Offered ADS will initially represent the right to receive one Ordinary Share deposited pursuant to the Deposit Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL....Exclusive License and Collaboration Agreement • September 27th, 2022 • Inventiva S.A. • Pharmaceutical preparations
This Exclusive License and Collaboration Agreement (the “Agreement”) is entered into as of September 21, 2022 (the “Effective Date”), by and between Inventiva S.A., a company incorporated under the laws of France, having its principal place of business at 50, rue de Dijon à Daix (21121), France (“Inventiva”), and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd., a limited liability company incorporated and existing under the laws of the People’s Republic of China, having its registered office located at No.369 South Yuzhou RD., HaiZhou District, Lianyungang, Jiangsu Province, Mainland China (“Licensee”).
SHAREHOLDERS AGREEMENTShareholders Agreement • April 3rd, 2024 • Inventiva S.A. • Pharmaceutical preparations
Catalys Pacific Fund II, LP (“Catalys”), Inventiva S.A. (“Inventiva”) and Hepalys Pharma, Inc. (the “Company”) enter into this Shareholders Agreement (this “Agreement”) on September 20th, 2023 in respect of the Company on the terms and conditions set forth below.
Subscription Agreement for T1 [Shares] [Pre-Funded Warrants]Subscription Agreement • October 15th, 2024 • Inventiva S.A. • Pharmaceutical preparations
Inventiva S.A., a société anonyme organized under the laws of the French Republic, with a share capital of €524,771.88, consisting of 52,477,188 ordinary shares of €0.01 nominal value each (the “Ordinary Shares” and each, an “Ordinary Share”), and registered with the Commerce and Companies Registry of Dijon under the number 537 530 255 (the “Company”), is contemplating a transaction (the “Transaction”) that consists of:
AMENDMENT No 4 TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • October 15th, 2024 • Inventiva S.A. • Pharmaceutical preparations
This FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Amendment #4”) is entered into as of October 11th, 2024 (the “Amendment #4 Effective Date”) by and between:
Royalty Certificate Subscription AgreementRoyalty Certificate Subscription Agreement • July 18th, 2024 • Inventiva S.A. • Pharmaceutical preparations
- that the necessity for plurality of originals, required by Article 1375 of the French civil Code, is satisfied for the Agreement, and that the process used to conclude the Agreement allows each party to have a copy on a durable support or to have access to it;
Royalty Certificate Subscription AgreementRoyalty Certificate Subscription Agreement • August 31st, 2023 • Inventiva S.A. • Pharmaceutical preparations
- that the necessity for plurality of originals, required by Article 1375 of the French civil Code, is satisfied for the Agreement, and that the process used to conclude the Agreement allows each party to have a copy on a durable support or to have access to it;
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 3rd, 2024 • Inventiva S.A. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of September 20th, 2023 (the “Effective Date”), by and between INVENTIVA S.A., a company incorporated under the laws of France, having its principal place of business at 50, rue de Dijon à Daix (21121), France (“Inventiva”), and Hepalys Pharma, Inc., a company incorporated under the laws of Japan, having its registered office located at 2-3-11, Nihonbashihoncho, Chuo-ku, Tokyo 103-0023 (“Licensee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 6th, 2020 • Inventiva S.A. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the 18th day of September, 2019 by and among Inventiva S.A., a société anonyme organized under the laws of the French Republic, (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
Subscription AgreementSubscription Agreement • August 31st, 2023 • Inventiva S.A. • Pharmaceutical preparations
